Bayer AG has agreed to postpone two upcoming trials in California accusing its weed killer Roundup of causing cancer diagnoses in consumers, Reuters reported. The first lawsuit, scheduled for Jan. 15, will be delayed for about six months, while a Jan. 21 case has been postponed for a date not yet determined.
Bayer faces about 42,7000 lawsuits in the United States from landscapers, groundskeepers, farmers and even home gardeners who say exposure to glyphosate, the active ingredient in Roundup, caused them to develop non-Hodgkin’s lymphoma. Bayer has been fighting cancer claims even though the World Health Organization’s International agency for Research on Cancer in 2015 classified glyphosate as a probable carcinogen based on studies of farmers exposed to the chemical.
Bayer said pushing back the trial dates will give the company and plaintiffs both time to “engage constructively in the mediation process.”
Most Roundup lawsuits are filed in state courts across the country. Others are consolidated in a federal multi-district litigation in Northern California.
Shortly after Bayer’s acquisition of Monsanto in 2018 for $63 billion, Bayer lost the first Roundup case to go to trial – in California state court – to the tune of $285 million. A judge later reduced the award to $78 million. The second case to go to trial, which was the first federal trial, ended with an $80 million verdict. That award was later reduced to $25.5 million. The third trial resulted in a stunning $2.055 billion verdict on behalf of an elderly couple who both developed non-Hodgkin’s lymphoma after regularly using Roundup on their property. That verdict was later reduced to $86.7 million.
Beasley Allen is investigating cases involving non-Hodgkin’s lymphoma related to the commercial application of Roundup/glyphosate. For more information or to discuss a possible claim, contact John Tomlinson, Danielle Ingram, Michael Dunphy or Rhon Jones.